Genentech and BioNTech to Collaborate on mRNAVaccines
By Jasmine Kalsi
Pharma Deals Review: Vol 2016 Issue 9 (Table of Contents)
Published: 30 Sep-2016
DOI: 10.3833/pdr.v2016.i9.2197 ISSN: 1756-7874
Section: Research & Development
Fulltext:
Abstract
Amidst cut-throat competition within the immuno-oncology space, Genentech aims to reinforce the potential of its anti-PD-L1 drug,Tecentriq® (atezolizumab), through a worldwide collaboration with German biotech, BioNTech, to develop combinations with its personalised mRNA vaccines...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS